STANDARD BIOTOOLS CEO RSU tax-withholding shares

STANDARD BIOTOOLS INC.

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a Form 4 showing a tax-related share disposition. On the transaction date, 66,127 shares of common stock were withheld at $1.15 per share to cover tax withholding obligations from vesting restricted stock units. After this tax-withholding disposition, Egholm directly owned 5,551,710 shares of common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 66,127 shares

Exercise Price or Tax Liability 1 txn

Insider Egholm Michael

Role President & CEO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	66,127	$1.15	$76K

Holdings After Transaction: Common Stock — 5,551,710 shares (Direct)

Footnotes (1)

1. F1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did STANDARD BIOTOOLS (LAB) report for Michael Egholm?

STANDARD BIOTOOLS President & CEO Michael Egholm reported a Form 4 tax-withholding disposition. The company withheld 66,127 common shares to satisfy tax obligations from vesting restricted stock units, rather than an open-market sale, and his direct holdings remained substantial afterward.

How many STANDARD BIOTOOLS (LAB) shares were withheld for Michael Egholm’s taxes?

STANDARD BIOTOOLS withheld 66,127 common shares for Michael Egholm’s tax obligations. The shares were valued at $1.15 per share and related to restricted stock units that vested from grants originally made in May 2024 and March 2025.

Was Michael Egholm’s Form 4 transaction in STANDARD BIOTOOLS (LAB) an open-market sale?

No, the Form 4 for Michael Egholm did not report an open-market sale. The 66,127 shares were withheld by STANDARD BIOTOOLS to cover tax withholding obligations triggered by vesting restricted stock units, which is a common administrative transaction for equity compensation.

What is Michael Egholm’s share ownership in STANDARD BIOTOOLS (LAB) after this Form 4?

After the tax-withholding disposition, Michael Egholm directly owned 5,551,710 shares of STANDARD BIOTOOLS common stock. This figure reflects his holdings following the 66,127 shares withheld to satisfy tax obligations from his vested restricted stock unit awards.

What caused the tax-withholding share disposition for STANDARD BIOTOOLS (LAB) CEO Michael Egholm?

The tax-withholding share disposition arose when Michael Egholm’s restricted stock units vested. STANDARD BIOTOOLS withheld 66,127 shares to satisfy related tax obligations from RSU grants made in May 2024 and March 2025, as previously reported on earlier Forms 4.

What price per share was used for the withheld STANDARD BIOTOOLS (LAB) shares?

The 66,127 STANDARD BIOTOOLS shares withheld for Michael Egholm’s taxes used a reference price of $1.15 per share. This price is disclosed in the Form 4 and is used to determine the value of the shares applied toward the tax obligation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 05:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Egholm Michael

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON MA 02109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		F		66,127(1)	D	$1.15	5,551,710	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively.

	/s/ Michael Egholm by Tomone Tanaka, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.